Last reviewed · How we verify
Ofloxacine — Competitive Intelligence Brief
phase 3
Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Ofloxacine (Ofloxacine) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ofloxacine TARGET | Ofloxacine | Assistance Publique - Hôpitaux de Paris | phase 3 | Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ofloxacine CI watch — RSS
- Ofloxacine CI watch — Atom
- Ofloxacine CI watch — JSON
- Ofloxacine alone — RSS
Cite this brief
Drug Landscape (2026). Ofloxacine — Competitive Intelligence Brief. https://druglandscape.com/ci/ofloxacine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing